PTH and secondary hyperparathyroidism: Reported that in clinical trials for pediatric patients with secondary hyperparathyroidism (SHPT) undergoing hemodialysis [32], 7.4–57.1% of subjects treated with cinacalcet achieved PTH levels within the recommended target range, while 22.2–70.6% experienced a PTH reduction of ≥30%.